Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

Minerva Neurosciences Stock Performance

Shares of Minerva Neurosciences stock opened at $2.51 on Wednesday. The business’s 50 day moving average price is $2.22 and its 200 day moving average price is $2.54. The company has a market cap of $17.54 million, a price-to-earnings ratio of -5.70 and a beta of 0.11. Minerva Neurosciences has a one year low of $2.03 and a one year high of $13.49.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.